11/20
11:42 am
inkt
MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors
Medium
Report
MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors
11/14
07:08 pm
inkt
MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation [Yahoo! Finance]
Medium
Report
MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation [Yahoo! Finance]
11/14
07:30 am
inkt
MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation
Low
Report
MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation
11/7
09:00 am
inkt
MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025
Medium
Report
MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025
11/5
09:07 am
inkt
MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development
Low
Report
MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development
10/30
09:35 am
inkt
MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting [Yahoo! Finance]
Low
Report
MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting [Yahoo! Finance]
10/30
09:00 am
inkt
MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
Low
Report
MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
10/25
12:09 pm
inkt
MiNK Therapeutics (NASDAQ:INKT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
MiNK Therapeutics (NASDAQ:INKT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/22
09:35 am
inkt
MiNK Therapeutics (NASDAQ:INKT) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Medium
Report
MiNK Therapeutics (NASDAQ:INKT) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
9/29
08:03 am
inkt
MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors [Yahoo! Finance]
Medium
Report
MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors [Yahoo! Finance]
9/29
07:30 am
inkt
MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors
Medium
Report
MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors
9/25
08:10 am
inkt
MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA [Yahoo! Finance]
Medium
Report
MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA [Yahoo! Finance]
9/25
07:30 am
inkt
MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA
Medium
Report
MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA
9/18
07:30 am
inkt
MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development
Medium
Report
MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development